On this occasion, we want to delve into the fascinating world of DelNS1-2019-nCoV-RBD-OPT. Whether you are interested in learning more about its history, understanding its importance in today's society or simply exploring its many applications, this article is designed to offer you a deep and complete insight into the topic. Through extensive analysis and careful research, we aim to provide you with relevant and up-to-date information that helps you better understand DelNS1-2019-nCoV-RBD-OPT and its impact on the world around us. No matter your level of prior knowledge on the topic, we hope you find this article informative, entertaining, and educational. Join us on this journey of discovery and learning about DelNS1-2019-nCoV-RBD-OPT!
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Trade names | Pneucolin |
Other names | DelNS1-nCoV-RBD LAIV |
Routes of administration | Intranasal |
DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine candidate developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong.
On 14 December 2022, the vaccine was listed by the National Health Commission of China as a secondary booster dose option for people who have completed their third doses of inactivated COVID-19 vaccines for 6 months or longer.
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |